- Home
- Equipment
- north america
- dermatitis atopic
Refine by
Dermatitis Atopic Equipment Supplied In North America
29 equipment items found
Manufactured by:Benevolent based inLondon, UNITED KINGDOM
Advancing a potent and selective Atopic Dermatitis treatment through the clinic. What is Atopic Dermatitis? Atopic Dermatitis (AD), the most common type of eczema, is a chronic relapsing inflammatory skin disease that results in itchy, red, swollen, and cracked skin. Our work : BEN-2293, a ...
Manufactured by:BiomX based inNess Ziona, ISRAEL
We are developing BX005, a topical phage cocktail that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. This program leverages know-how and capabilities acquired under our previous programs with regard to topical formulation and clinical testing. In preclinical in vitro studies, BX005 was shown to be active against over 90% of strains of S. ...
Manufactured by:Siolta Therapeutics based inSan Carlos, CALIFORNIA (USA)
The Power to Prevent: Allergic diseases, including atopic dermatitis, food allergy, allergic asthma, and allergic rhinitis, have a common underlying inflammatory cascade and often occur in a sequential order referred to as “the atopic march.” STMC-103H, also known as adored: allergic disease onset prevention study, is Siolta’s ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
Etokimab (Anti-IL-33) is a humanized monoclonal antibody that targets IL-33. It can be used for the research of atopic dermatitis. MW :146.56 ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
Amlitelimab (Anti-TNFSF4 / OX40L / CD252) is a nondepleting IgG4 human anti-OX40L monoclonal antibody with the potential to treat atopic dermatitis. MW: 145.94 ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
Tralokinumab (Anti-IL-13) is a fully human IgG4 monoclonal antibody specifically targeting IL-13 with high affinity. It can be used for the research of the atopic dermatitis (AD). MW :145.5 ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
Anti-IL-17c is a fully humanized recombinant IgG1 monoclonal antibody targeting IL-17C. It can be used in a clinical treatment of atopic dermatitis. MW :145.5 ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
It inhibits the binding of interleukin-31 (IL-31) to its receptor and subsequent signal transduction. Nemolizumab can used be in research of atopic dermatitis (AD). MW:145.5 ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
Anti-IL-22Ra is an affinity isolated polyclonal antibody, targeting IL-22R. It is used in the treatment of psoriasis, psoriatic arthritis, atopic dermatitis. MW :145.5 ...
Manufactured by:SEQENS Group based inÉcully, FRANCE
It is the first JAK inhibitor approved by the FDA to treat patients with advanced stages of myelofibrosis and polycythemia vera (PV). The drug-treated population of atopic dermatitis may grow to 24 million and market is expected to grow to $18.3B by ...
Manufactured by:SEQENS Group based inÉcully, FRANCE
Fluticasone is a steroid with glucocorticoid receptor activity that is used to manage the symptoms of asthma; allergic rhinitis, and atopic ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Clobetasone butyrate is a synthetic glucocorticoid and has topical anti-inflammatory activity especially in skin. Clobetasone butyrate can be used to relieve corticosteroid-responsive dermatoses, including atopic?dermatitis and ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Rocatinlimab (AMG 451) (KHK4083) is a fully human, non-fucosylated, immunoglobulin G1 (IgG1) anti-OX40 monoclonal antibody. Rocatinlimab can be used for the research of atopic dermatitis ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Zelnecirnon (RPT193) is an orally active inhibitor of CCR4, blocks the recruitment of Th2 inflammatory immune cells into inflamed tissues. Zelnecirnon can be used for allergic inflammation in atopic dermatitis, asthma, and other diseases ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Alclometasone (7a-Chloro-16a-methyl prednisolone) is a glucocorticoid and inhibits the release of pro-inflammatory mediators from leukocytes. Alclometasone can be used to relieve corticosteroid-responsive dermatoses, including atopic?dermatitis, eczema, psoriasis and allergic ...
Manufactured by:Bausch Health Companies Inc. based inLaval, QUEBEC (CANADA)
Through new product development, growth of established brands and strategic acquisitions, the Ortho Dermatologics business has become one of the largest prescription dermatology companies in the world and a leader in the U.S. medical dermatology market. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Triamcinolone acetonide activates macrophage with anti-inflammatory characteristics. Triamcinolone acetonide can be used in the study of diseases such as atopic ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Methylisothiazolinone can activate matrix metalloproteinases (MMPs) in human bronchial epithelial cells to induce apoptosis and inflammatory response. Methylisothiazolinone can promote the development of atopic dermatitis in mice by disrupting Th2/Th17 related immune responses. Methylisothiazolinone can cause mitochondrial damage in the endothelium of rat ...
Manufactured by:AOBiome Therapeutic, LLC based inCambridge, MASSACHUSETTS (USA)
We have completed six Phase 2 clinical programs and multiple pre-clinical programs. Over 1,000 patients have been enrolled in our clinical trials since 2016. All of those patients except for 28 in our open label pediatric study have been enrolled in randomized double-blind placebo controlled clinical trials evaluating both topical and intranasal routes of delivery of AOB with treatment durations ...